1. Introduction {#sec1}
===============

Type 2 diabetes mellitus (T2DM) is one of the most common noncommunicable diseases characterized by insulin resistance and impaired insulin secretion \[[@B1], [@B2]\]. Metabolic proinflammatory disorder including chronic hyperglycemia and increased levels of circulating cytokines suggests immunological disturbances \[[@B3]--[@B7]\], which seriously affects the quality of life of the patients and imposes a large economic burden on the national health care system \[[@B8]\]. Genetic and environmental factors are blamed for T2DM and up to 25% of first-degree relatives of T2DM patients may develop this disease \[[@B9]\]. The origin and development of T2DM were involved in multiple risk factors \[[@B10]\]. Regulatory T cells (Treg) and cytokines play important roles in the development of T2DM.

Treg is a subset of CD4^+^ T cells that maintain peripheral tolerance and suppress antigen specific immune responses by secreting transforming growth factor-*β* (TGF-*β*), interleukin-10 (IL-10), and IL-4 to inhibit autoimmunity \[[@B11]\]. It was found that the ratios of CD4^+^CD25^hi^Treg/Th17 cells and CD4^+^CD25^hi^Treg/Th1 cells were significantly decreased in T2DM patients \[[@B12]\]. Expression of Foxp3, a key player for the development and function of Treg, correlates well with regulatory activity and number of Treg. Indeed, Foxp3 is exclusively expressed in CD4^+^CD25^+^Treg \[[@B13]--[@B16]\]. A positive correlation between CD4^+^CD25^+^Foxp3^+^Treg and the enhanced expression of IL-6 on CD4^+^ T cells was observed in T2DM patients \[[@B17]\]. IL-10, as a multifunctional cytokine and secretion of Treg, plays a key role in the inflammatory response that is associated with insulin resistant states and T2DM \[[@B18]\]. Increased levels of IL-17 were found to protect against autoimmune mediated T1DM in nonobese diabetic mice \[[@B19]\]. On the other hand, loss of IL-17 has been associated with disease susceptibility in part because it has been suggested that the absence of IL-17 results in enhanced production of other proinflammatory cytokines \[[@B20]\]. TGF-*β* is also a multifunctional cytokine circulating as a biologically inactive form in human plasma \[[@B21], [@B22]\]. The TGF-*β* family includes multifunctional molecules that exert specific effects on cell proliferation, differentiation, migration, development, tissue remodeling, and repair \[[@B23]\]. TNF-*α* inhibits the insulin signaling cascade through regulating several pivotal regulatory proteins, such as the insulin receptor substrate (IRS) and Akt substrate 160 in human skeletal muscle*in vitro* \[[@B24]\] and*in vivo* \[[@B25]\]. It has reported that polymorphism of immune genes such as TNF-*α* \[[@B26]\] and TGF-*β* \[[@B27]\] was associated with the development of T2DM. Intriguingly, increased renal production of TGF-*β* was a distinct feature of diabetes \[[@B28]--[@B31]\].

Within the past few years, many clinical studies have been focusing on the association of Treg with proinflammatory and immunosuppressive cytokines in T2DM. Despite intensive research efforts, results of these studies have been inconsistent. Therefore, we performed this meta-analysis synthesizing the data from case-control studies to evaluate changes of Treg, IL-6, IL-10, IL-17, TGF-*β*, and TNF-*α* in T2DM patients.

2. Materials and Methods {#sec2}
========================

2.1. Study Identification and Search Strategy {#sec2.1}
---------------------------------------------

Our study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria \[[@B32]\]. We identified relevant studies of Treg, IL-6, IL-10, IL-17, TGF-*β*, and TNF-*α* in T2DM patients by systematically searching PubMed, Wanfang database, Chinese-Cqvip, and CNKI databases from February 1, 1991, to July 15, 2016. The search terms used were as follows: ("interleukin-6" or "IL-6") or ("interleukin-10" or "IL-10") or ("interleukin-17" or "IL-17") or ("transforming growth factor beta" or "TGF-*β*") or ("tumor necrosis factor alpha" or "TNF-*α*") or ("regulatory T cells" or "Treg" or "CD4^+^CD25^+^ T cell" or "CD4^+^CD25^+^Foxp3^+^ T cell") and ("type 2 diabetes mellitus" or "type 2 diabetes" or "diabetes mellitus" or "diabetic patients" or "T2DM" or "DM"). In addition, we also conducted an extensive literature search and articles were further identified in reference lists. Data published in either English or Chinese were included.

2.2. Inclusion Criteria {#sec2.2}
-----------------------

We reviewed all relevant articles using the following inclusion criteria: (1) the study should evaluate the relationship of CD4^+^CD25^+^Foxp3^+^Treg, CD4^+^CD25^+^Treg, IL-6, IL-10, IL-17, TGF-*β*, or TNF-*α* with T2DM patients; (2) the design had to be a case-control study; (3) original data were displayed or could be converted to as mean ± SD; and (4) original report showed no duplicated data.

2.3. Quality Assessment and Data Extraction {#sec2.3}
-------------------------------------------

The data were extracted independently by two reviewers (Yong-chao Qiao and Jian Shen) by using predefined data extraction forms and the quality of all eligible studies was evaluated according to the Newcastle-Ottawa Scale (NOS) \[[@B33]\]. The following information was extracted: (1) name of the first author; (2) date of publication; (3) country of the study; (4) study design; (5) sample size of patients and controls; (6) mean age of the sample; and (7) mean ± SD of patients and controls. In case of disagreement, a third investigator (Hai-lu Zhao) was invited to assess such articles and the disagreements were resolved through discussion.

2.4. Statistical Analysis {#sec2.4}
-------------------------

We presented the data (sample size, mean ± SD) to illustrate the changes of Treg, IL-6, IL-10, IL-17, TGF-*β*, and TNF-*α* in T2DM patients versus healthy controls, and Chi-squared *Q* test and *I* ^2^ statistics were used to assess heterogeneity. When *p* \< 0.1 or *I* ^2^ \> 50%, the heterogeneity was considered significant and a random effect model was used; otherwise, a fixed-effect model was used. Considering the influence of diabetic complications, patients were divided into two groups (T2DM with complication and T2DM without complication) for subgroup analysis. Regression analysis is also an important method for exploring sources of heterogeneity. We performed sensitivity analysis by limiting the studies of NOS score ≥ 7 or excluding studies with a high risk of bias. Publication bias was examined graphically by constructing Egger\'s test and *p* \< 0.05 was considered to be representative of statistically significant publication bias. Stata 12.0 software was performed in this meta-analysis.

3. Results {#sec3}
==========

3.1. The Process and Results of Selection {#sec3.1}
-----------------------------------------

The flow chart of the article search and inclusion process was displayed in [Figure 1](#fig1){ref-type="fig"}. Based on the search strategy, a total of 5,064 articles were collected and 332 were removed after our initial screening. Furthermore, 3,954 articles were excluded because they were not DM relevant, have no controls, or were animal studies or review articles. Then, we excluded 687 studies because of duplicated data, no original data, or original data expressed with figures. Eventually, this meta-analysis included 91 articles involving 138 case-control studies of 5642 T2DM patients and 7378 healthy controls: 13 for IL-6 \[[@B34]--[@B46]\], 22 for TGF-*β* \[[@B23], [@B47]--[@B67]\], 7 for TNF-*α* \[[@B34]--[@B36], [@B38], [@B45], [@B68], [@B69]\], 6 for CD4^+^CD25^+^Foxp3^+^Treg \[[@B70]--[@B75]\], 15 for IL-10 \[[@B76]--[@B90]\], 18 for CD4^+^CD25^+^Treg \[[@B70], [@B72], [@B74], [@B75], [@B91]--[@B104]\], and 10 for IL-17 \[[@B105]--[@B114]\]. Main characteristics of the 91 included studies were listed in Tables [1](#tab1){ref-type="table"} [](#tab2){ref-type="table"} [](#tab3){ref-type="table"} [](#tab4){ref-type="table"} [](#tab5){ref-type="table"} [](#tab6){ref-type="table"}--[7](#tab7){ref-type="table"}. The case-control study of T2DM with complication was labelled with "*∗*". NOS results showed high methodological quality.

3.2. Results of Meta-Analysis {#sec3.2}
-----------------------------

Compared with the controls, T2DM patients had significantly increased levels of serum IL-6 (SMD, 1.28; 95% CI, 0.73 to 1.83; *p* \< 0.001) ([Figure 2](#fig2){ref-type="fig"}), TGF-*β* (SMD, 2.88; 95% CI, 2.37 to 3.40; *p* \< 0.001) ([Figure 3](#fig3){ref-type="fig"}), and TNF-*α* (SMD, 1.56; 95% CI, 1.10 to 2.02; *p* \< 0.001) ([Figure 4](#fig4){ref-type="fig"}) but significantly decreased the percentage of CD4^+^CD25^+^Foxp3^+^Treg (SMD, −0.47; 95% CI, −0.72 to −0.23; *p* \< 0.001) ([Figure 5](#fig5){ref-type="fig"}) and the level of serum IL-10 (SMD, −1.37; 95% CI, −2.32 to −0.42; *p* = 0.005) ([Figure 6](#fig6){ref-type="fig"}). Changes in the percentage of CD4^+^CD25^+^Treg (SMD, −0.24; 95% CI, −0.76 to 0.28; *p* = 0.360) ([Figure 7](#fig7){ref-type="fig"}) and IL-17 (SMD, −0.51; 95% CI, −1.87 to 0.84; *p* = 0.459) ([Figure 8](#fig8){ref-type="fig"}) were not significant. Some but not all the results of the meta-analysis displayed significant heterogeneity.

3.3. Subgroup Analysis and Regression Analysis {#sec3.3}
----------------------------------------------

Subgroup analysis was performed to explore the impact of diabetic complication on the changes in Treg and cytokines. As shown in Figures [2](#fig2){ref-type="fig"} [](#fig3){ref-type="fig"} [](#fig4){ref-type="fig"} [](#fig5){ref-type="fig"} [](#fig6){ref-type="fig"} [](#fig7){ref-type="fig"}--[8](#fig8){ref-type="fig"}, both T2DM patients with complication and the patients without complication had significantly increased levels of serum IL-6 ([Figure 2](#fig2){ref-type="fig"}), TGF-*β* ([Figure 3](#fig3){ref-type="fig"}), and TNF-*α* ([Figure 4](#fig4){ref-type="fig"}), while not significant changes were found in the percentage of peripheral CD4^+^CD25^+^Treg ([Figure 7](#fig7){ref-type="fig"}) and IL-17 ([Figure 8](#fig8){ref-type="fig"}). Intriguingly, T2DM patients with complication showed lower percentage of peripheral CD4^+^CD25^+^Foxp3^+^Treg (*p* \< 0.001) ([Figure 5](#fig5){ref-type="fig"}), whereas patients without complication had decreased levels of serum IL-10 (*p* = 0.033) ([Figure 6](#fig6){ref-type="fig"}).

The high heterogeneity existed in some subgroup analysis. In order to explore the source of heterogeneity, we further conducted regression analysis according to the complication as covariate. The results were as follows: TGF-*β* (*t* = 4.08; *p* \< 0.001; 95% CI, 1.23 to 3.65), IL-6 (*t* = 0.09; *p* = 0.929; 95% CI, −1.09 to 1.18), TNF-*α* (*t* = 0.34; *p* = 0.740; 95% CI, −1.23 to 1.67), CD4^+^CD25^+^Foxp3^+^Treg (*t* = −2.04; *p* = 0.097; 95% CI, −1.55 to 0.18), IL-10 (*t* = −0.36; *p* = 0.723; 95% CI, −5.33 to 3.77), CD4^+^CD25^+^Treg (*t* = 0.63; *p* = 0.534; 95% CI, −0.96 to 1.81), and IL-17 (*t* = −0.56; *p* = 0.586; 95% CI, −4.84 to 2.86). Therefore, diabetic complication was a key influencing factor for the high heterogeneity in the meta-analysis of TGF-*β* but not the others.

3.4. Sensitivity Analysis {#sec3.4}
-------------------------

Sensitivity analysis was used to assess the stability of the results by excluding studies with high risk of bias and no significant changes in the results were found. We further conducted sensitivity analysis by including studies with high NOS score (≥7) and found that all the results remained consistent.

3.5. Publication Bias {#sec3.5}
---------------------

Egger\'s test showed significant publication bias in the meta-analysis of TNF-*α* but not the others ([Figure 9](#fig9){ref-type="fig"}).

4. Discussion {#sec4}
=============

In this study, we found that the patients with T2DM had increased serum levels of IL-6, TGF-*β*, and TNF-*α* but decreased percentage of peripheral CD4^+^CD25^+^Foxp3^+^Treg and serum IL-10 level. Furthermore, the percentage of peripheral CD4^+^CD25^+^Foxp3^+^Treg and serum IL-10 level were influenced by diabetic complication.

The expression of inflammatory and proinflammatory cytokines from peripheral blood T lymphocyte plays an important role in the development of diabetes and diabetic complications \[[@B17]\]. Many studies have proved the maintenance of immunological self-tolerance by CD4^+^CD25^+^Treg and CD4^+^CD25^+^Foxp3^+^Treg \[[@B115]\]. Treg could suppress inflammatory response through contact inhibition \[[@B116]\]. In this study, the finding of decreased percentage of peripheral CD4^+^CD25^+^Foxp3^+^Treg in T2DM patients indicates that Foxp3 might be a key player for the development and function of Treg. CD4^+^CD25^+^Foxp3^+^Treg differs from CD4^+^CD25^+^Treg. CD4^+^CD25^+^Treg might not sufficiently represent the negative regulatory Treg. Some researchers also considered that the differentiation and function maintenance of Treg were dependent on the expression of the Foxp3, and, consequently, Foxp3 is considered as the key transcriptional factor in Treg cells \[[@B117]--[@B119]\].

IL-10 and TGF-*β* secreted by Treg \[[@B116], [@B120]\] are the biomarkers in T2DM patients \[[@B2], [@B116]\]. Previous studies suggested that IL-10 could suppress the proliferation of T leukomonocyte and the secretion of cytokines \[[@B121]\], whereas TGF-*β* may sustain the expression of Foxp3 in CD4^+^CD25^+^Treg to enhance immunosuppressive function \[[@B122], [@B123]\]. Consistent with our findings, several studies have shown a significantly decreased level of serum IL-10 in T2DM patients \[[@B88], [@B124]\]. Correlation of T2DM with Treg cells and TGF-*β* is generally negative \[[@B116]\].

IL-6 can be released from macrophages and adipocytes in adipose tissue \[[@B125]--[@B127]\]. Adipose tissue also produces TNF-*α* to stimulate IL-6 gene expression \[[@B128]\]. A recent investigation has showed that IL-6 could enhance Treg in mice \[[@B129]\]. In the present meta-analysis of T2DM patients, increased levels of serum IL-6, TGF-*β*, and TNF-*α* coexisted with decreased levels of IL-10 and decreased percentage of CD4^+^CD25^+^Foxp3^+^Treg. This finding highlights that the cytokines and growth factors may originate from multiple sources such as macrophages, T cells, and other tissue cells rather than Treg alone. Furthermore, chronic persistent activation of innate immunity and IL-6 secretion occurring in T2DM might inhibit the development of inducible Treg cells.

Th17 cells could produce IL-17, TNF-*α*, and IL-6 and induce inflammation in the pathogenesis of autoimmune diseases \[[@B130]\]. Th17 cells are a major T cell subset implicated in the pathogenesis of multiple sclerosis, rheumatoid arthritis, and psoriasis \[[@B131]\]. A previous study has revealed that not only Th1/Th2 imbalance but also Th17/Treg imbalance can contribute to the pathogenesis of autoimmune diseases such as T1DM as well as proinflammatory disorders and such as T2DM \[[@B2]\]. T2DM patients have elevated serum levels of IL-6, IL-1*β*, and TGF-*β*, the cytokines known to induce Th17 differentiation \[[@B131]\]. Enhanced production of IL-6 and TNF-*α* and decreased levels of serum IL-10 that occurred in T2DM patients may suppress Treg cells and ratios of Treg to Th17 and Th1 cells \[[@B132], [@B133]\]. The immunocompromised effects on macrophages and lymphocytes likely drive an inflammatory state to contribute to the occurrence of diabetic complications \[[@B12]\]. Here, in this study, no significant changes of Foxp3^+^Treg cells and serum IL-17 levels were found in T2DM subjects without complication. In contrast, decreased Foxp3^+^Treg cells were evident in T2DM subjects with complication. These findings indicate a close correlation of CD4^+^CD25^+^Foxp3^+^Treg and diabetic complication in T2DM.

There is an intimate relationship of the differentiation of Th17 cells with the relative abundance of peripheral CD4^+^CD25^+^Foxp3^+^Treg cells and the serum levels of IL-6, IL-10, and TGF-*β*. Although changes of serum levels of IL-17 were not significant in this meta-analysis of T2DM patients versus controls, IL-17 may be a clue to the possible involvement of Th17 cells in T2DM pathogenesis. Firstly, a decrease of Treg cells might be accompanied by an increase of Th17 cells. The study by Guan et al. has indicated the existence of a developmental switch between Th1/Th17 cells, on one hand, and Th2/Treg cells, on the other hand \[[@B134]\]. Secondly, in the presence of high serum levels of IL-6 and TGF-*β*, as we reported here, differentiation of Th17 cells might be favoured. Lastly, Th17 cells might be, together with innate cells, a primary source of the increased IL-6 levels and might be actively orchestrating the immunity-driven, chronic inflammation of target tissues and organs in T2DM. In this systematic review, the studies examining the number of Th17 cells in T2DM were too scarce for being included in the meta-analysis. Future studies are required to focus on the role of Th17/Treg and products of the Th17 cells in the pathogenesis of T2DM and associated complications.

Diabetic complications such as retinopathy, nephropathy, and cardiovascular disease affect immune cells and cytokines in type 2 diabetes \[[@B135], [@B136]\]. Actually, urinary TGF-*β* levels are elevated in the presence of microalbuminuria and overt proteinuria \[[@B137]\]. Additionally, elevated plasma TGF-*β* may reflect the state of hyperglycemia in T2DM patients \[[@B48]\]. Systemic inflammation in T2DM is linked to the development of diabetic complications \[[@B138], [@B139]\]. Yet, the mechanism of immune alteration in T2DM and diabetic complication remains unclear. In this meta-analysis, diabetic complication indeed has an impact on the percentage of peripheral CD4^+^CD25^+^Foxp3^+^Treg and level of serum IL-10. The percentage of Treg cells and levels of cytokines in T2DM may also depend on ethnicity, sex, weight, age, and disease duration.

Publication bias might influence the interpretation of our final results. The results of Egger\'s tests explain that no publication bias existed in all comparisons except for TNF-*α*. The publication bias in this meta-analysis might be attributed to studies of small samples and positive results published more easily than negative reports.

There are some limitations in this meta-analysis when interpreting the findings. Firstly, we have selected random effect model to synthesize SMD because of the high heterogeneity existing in some comparisons, but this selection may affect the accuracy of outcome. Secondly, we could not conduct further subgroup analysis of gender, weight, and disease duration because most of the included studies lack sufficient original data. Thirdly, articles published in Chinese or English are included, while unpublished data and papers published in other languages are unknown.

5. Conclusions {#sec5}
==============

In summary, T2DM patients and the patients with diabetic complication have decreased immunosuppressive CD4^+^CD25^+^Foxp3^+^Treg cells and increased proinflammatory IL-10, TGF-*β*, and TNF-*α*. The presence of diabetic complication has an impact on the compromised immunosuppression. Significant interaction exists between immune and metabolic homeostasis.

The authors would like to thank Mr. Golden Wilson for his English proofing. Funding for this work was provided by the National Natural Science Foundation of China (81471054) and the Innovation Project of Guangxi Graduate Education (JGY2015128).

T2DM:

:   Type 2 diabetes mellitus

Treg:

:   Regulatory T cells

IL-6:

:   Interleukin-6

IL-10:

:   Interleukin-10

IL-17:

:   Interleukin-17

TGF-*β*:

:   Transforming growth factor-beta

TNF-*α*:

:   Tumor necrosis factor-alpha.

Competing Interests
===================

The authors declare that they have no competing interests.

Authors\' Contributions
=======================

Yong-chao Qiao designed the study, implemented the study protocol, collected and analyzed data, and wrote the first daft. Jian Shen directed statistical analyses of the data and designed the study. Lan He, Xue-zhi Hong, Fang Tian, Yan-hong Pan, Ling Liang, and Xiao-xi Zhang analyzed and interpreted the data. Hai-lu Zhao designed the study, wrote the manuscript, and revised the submission. All authors contributed to the discussion and approved the submission of the final manuscript. Yong-chao Qiao and Jian Shen contributed equally to this paper.

![A flow chart of the article search and inclusion process.](JDR2016-3694957.001){#fig1}

![Forest plots for serum IL-6 in T2DM patients and controls with random effects model (T2DM without complication, *p* = 0.002; T2DM with complication, *p* \< 0.001; overall, *p* \< 0.001). ^*∗*^T2DM with complication.](JDR2016-3694957.002){#fig2}

![Forest plots for serum TGF-*β* in T2DM patients and controls with random effects model (T2DM without complication, *p* \< 0.001; T2DM with complication, *p* \< 0.001; overall, *p* \< 0.001). ^*∗*^T2DM with complication. ^*∗∗*^T2DM with different complication.](JDR2016-3694957.003){#fig3}

![Forest plots for serum TNF-*α* in T2DM patients and controls with random effects model (T2DM without complication, *p* \< 0.001; T2DM with complication, *p* \< 0.001; overall, *p* \< 0.001). ^*∗*^T2DM with complication.](JDR2016-3694957.004){#fig4}

![Forest plots for the frequency of CD4^+^CD25^+^Foxp3^+^Treg in T2DM patients and controls with random effects model (T2DM without complication, *p* = 0.211; T2DM with complication, *p* \< 0.001; overall, *p* \< 0.001). ^*∗*^T2DM with complication. ^*∗∗*^T2DM with different complication.](JDR2016-3694957.005){#fig5}

![Forest plots for serum IL-10 in T2DM patients and controls with random effects model (T2DM without complication, *p* = 0.033; T2DM with complication, *p* = 0.076; overall, *p* = 0.005). ^*∗*^T2DM with complication.](JDR2016-3694957.006){#fig6}

![Forest plots for the frequency of CD4^+^CD25^+^Treg in T2DM patients and controls with random effects model (T2DM without complication, *p* = 0.053; T2DM with complication, *p* = 0.987; overall, *p* = 0.360). ^*∗*^T2DM with complication. ^*∗∗*^T2DM with different complication.](JDR2016-3694957.007){#fig7}

![Forest plots for serum IL-17 in T2DM patients and controls with random effects model (T2DM without complication, *p* = 0.969; T2DM with complication, *p* = 0.269; overall, *p* = 0.459). ^*∗*^T2DM with complication.](JDR2016-3694957.008){#fig8}

![Egger\'s test about the Treg and cytokines for publication bias ((a) IL-6,*t* = 1.31,*p* = 0.209, CI, −2.46 to 10.33; (b) TGF-*β*,*t* = 1.20,*p* = 0.238, CI, −1.20 to 4.69; (c) TNF-*α*,*t* = 3.98,*p* = 0.004, CI, 2.52 to 9.49; (d) CD4^+^CD25^+^Foxp3^+^Treg,*t* = −1.22,*p* = 0.277, CI, −22.58 to 8.05; (e) IL-10,*t* = −1.26,*p* = 0.223, CI, −15.80 to 3.93; (f) CD4^+^CD25^+^Treg,*t* = −0.95,*p* = 0.351, CI, −11.97 to 4.43; (g) IL-17,*t* = −0.20,*p* = 0.845, CI, −26.99 to 22.44).](JDR2016-3694957.009){#fig9}

###### 

Characteristics of studies about IL-6 (pg/mL) included in this meta-analysis.

  Author                        Year   Country   Case   Control   NOS score                                          
  ----------------------------- ------ --------- ------ --------- ----------- ------- ----- --------- ------- ------ ---
  Plomgaard^a^ \[[@B34]\]       2007   Denmark   96     72/24     1.63        1.22    103   70/33     1.27    1.04   7
  Volpe \[[@B35]\]              2014   Brazil    29     10/19     119.1       23.3    16    5/11      97.6    13.5   8
  Yeo \[[@B36]\]                2010   Korea     55     27/28     2.3         0.35    488   257/231   1.8     0.11   8
  Kado^*∗*^ \[[@B37]\]          1999   Japan     57     NR        3.48        3.29    15    NR        0.784   0.9    7
  Lukic \[[@B38]\]              2014   Serbia    30     NR        11.77       6.09    15    NR        3.48    1.48   8
  Lukic^*∗*^ \[[@B38]\]         2014   Serbia    30     NR        15.46       5.15    15    NR        3.48    1.48   8
  Hansen^*∗*,a^ \[[@B39]\]      2012   Denmark   8      NR        4.6         5.2     8     NR        1.4     1.15   7
  Andriankaja \[[@B40]\]        2009   USA       30     NR        1.5         1.4     310   NR        1.8     2.3    8
  Andriankaja^*∗*^ \[[@B40]\]   2009   USA       50     NR        2.9         3.2     310   NR        1.8     2.3    8
  Guzel \[[@B41]\]              2013   Turkey    28     NR        3.21        1.24    30    19/14     1.73    0.93   8
  Guzel^*∗*^ \[[@B41]\]         2013   Turkey    17     NR        6.67        2.67    30    19/14     1.73    0.93   8
  Aso \[[@B42]\]                2003   Japan     42     22/20     3.15        1.53    48    NR        1.29    0.52   7
  Lim^a^ \[[@B43]\]             2004   England   56     31/25     1.9         8.02    39    21/18     1       1.59   8
  Lim^*∗*,a^ \[[@B43]\]         2004   England   41     30/11     2.6         26.95   39    21/18     1       1.59   7
  Hui^*∗*^ \[[@B44]\]           2015   China     48     20/28     16.17       8.36    20    13/7      5.2     2.03   8
  Daniele \[[@B45]\]            2014   USA       17     13/4      2.1         0.4     15    7/8       1.7     0.4    8
  Głowińska \[[@B46]\]          2003   Polish    28     NR        6.5         1.4     15    NR        2.3     2.3    7

DM: diabetes mellitus; SZ: sample size; M/F: man/female; SD: standard deviation; NR: not reported. ^*∗*^T2DM with complication and ^a^data (mean ± SD) converted from mean (95% CI).

###### 

Characteristics of studies about TGF-*β* (*μ*g/L) included in this meta-analysis.

  Author                      Year   Country   Case   Control   NOS score                                               
  --------------------------- ------ --------- ------ --------- ----------- -------- ------ --------- -------- -------- ---
  Azar \[[@B47]\]             1999   Lebanon   26     8/18      0.558       0.107    27     10/17     0.593    0.064    8
  Azar^a^ \[[@B48]\]          2000   Lebanon   8      3/5       10.8        2.3      15     9/6       4.1      0.5      8
  Azar^b^ \[[@B48]\]          2000   Lebanon   9      2/7       9.9         2.8      15     9/6       4.1      0.5      8
  Azar^c^ \[[@B48]\]          2000   Lebanon   8      5/3       10.7        2.2      15     9/6       4.1      0.5      8
  Jun-Wen \[[@B49]\]          2007   China     61     35/26     315.9       224.59   19     10/9      68.47    31.75    7
  Chi \[[@B50]\]              2013   China     20     11/9      18.55       2.67     18     10/8      8.97     4.087    8
  Chi^*∗*^ \[[@B50]\]         2013   China     20     9/11      19.04       2.87     18     10/8      8.97     4.087    8
  Chi^*∗∗*^ \[[@B50]\]        2013   China     21     13/8      18.12       3.17     18     10/8      8.97     4.087    8
  Ehnert \[[@B51]\]           2015   Germany   14     7/7       35.3        2.4      13     7/6       39.5     1.4      8
  Changxin \[[@B52]\]         2007   China     34     24/10     36.2        8.8      35     24/11     34.4     8.2      7
  Changxin^*∗*^ \[[@B52]\]    2007   China     31     21/10     69.4        12.8     35     24/11     34.4     8.2      7
  Hellmich \[[@B53]\]         2000   Germany   35     16/19     9.5         2.1      12     5/7       0.24     0.03     8
  Hellmich^*∗*^ \[[@B53]\]    2000   Germany   23     8/15      10.8        2.1      12     5/7       0.24     0.03     8
  Herder \[[@B54]\]           2009   Germany   460    255/205   35.8        0.4      1474   724/750   35       0.2      8
  Hai-bing \[[@B55]\]         2001   China     14     7/7       35.02       6.7      15     7/8       23.95    8.01     6
  Hai-bing^*∗*^ \[[@B55]\]    2001   China     13     5/8       58.58       9.56     15     7/8       23.95    8.01     6
  Hai-bing^*∗∗*^ \[[@B55]\]   2001   China     18     9/9       39.31       5.35     15     7/8       23.95    8.01     6
  Zhen-zuo \[[@B56]\]         2005   China     27     14/13     41          15.57    18     9/9       10.04    5.33     7
  Zhen-zuo^*∗*^ \[[@B56]\]    2005   China     12     7/5       66.35       18.04    18     9/9       10.04    5.33     7
  Zhen-zuo^*∗∗*^ \[[@B56]\]   2005   China     18     9/9       53.31       15.64    18     9/9       10.04    5.33     7
  Rui-Ji \[[@B57]\]           2011   China     32     NR        35          5        20     NR        25       5        6
  Rui-Ji^*∗*^ \[[@B57]\]      2011   China     31     NR        69          7        20     NR        25       5        6
  Rui-Ji^*∗∗*^ \[[@B57]\]     2011   China     32     NR        54          6        20     NR        25       5        6
  Da-wei^*∗*^ \[[@B58]\]      2013   China     15     NR        234.2       29.8     45     NR        69.4     12.5     7
  Da-wei^*∗∗*^ \[[@B58]\]     2013   China     32     NR        155.6       19.3     45     NR        69.4     12.5     7
  Pfeiffer \[[@B59]\]         1996   Germany   44     22/22     7.9         1        28     16/12     3.1      0.4      8
  Yan-Jun \[[@B60]\]          2002   China     34     16/18     147.03      22.57    35     17/18     136.97   37.96    7
  Yan-Jun^*∗*^ \[[@B60]\]     2002   China     31     15/16     170.65      18.74    35     17/18     136.97   37.96    7
  Yaping \[[@B61]\]           2008   China     44     NR        35.4        7.1      35     NR        32.5     6.8      7
  Yaping^*∗*^ \[[@B61]\]      2008   China     32     NR        68.2        12.5     35     NR        32.5     6.8      7
  Ye-Sheng \[[@B62]\]         2005   China     92     42/50     36.89       9.75     105    50/55     25.46    7.88     6
  Ye-Sheng^*∗*^ \[[@B62]\]    2005   China     91     40/51     41.57       10.55    105    50/55     25.46    7.88     6
  Ming-bin \[[@B63]\]         2002   China     15     NR        25.85       6.09     15     8/7       21.4     5.62     6
  Ming-bin^*∗*^ \[[@B63]\]    2002   China     18     NR        38.53       3.98     15     8/7       21.4     5.62     6
  Ming-bin^*∗∗*^ \[[@B63]\]   2002   China     16     NR        31.15       3.51     15     8/7       21.4     5.62     6
  Chun-Yan \[[@B64]\]         2005   China     92     NR        45.57       21.78    20     NR        24.58    12.61    7
  Yener \[[@B23]\]            2008   Turkey    39     18/21     29.84       7.04     30     16/14     11.37    4.06     8
  Yuan \[[@B65]\]             2011   China     51     37/14     1.7399      0.4846   55     40/15     2.1045   0.5327   7
  Wei-jie \[[@B66]\]          2007   China     36     19/17     23.35       3.7      40     23/17     20.35    3.7      7
  Wei-jie^*∗*^ \[[@B66]\]     2007   China     45     25/20     55.28       6.8      40     23/17     20.35    3.7      7
  Wei-jie^*∗∗*^ \[[@B66]\]    2007   China     45     23/22     41.31       4.3      40     23/17     20.35    3.7      7
  Zhou \[[@B67]\]             2005   China     30     NR        31.12       12.39    30     NR        29.4     10.62    8
  Zhou^*∗*^ \[[@B67]\]        2005   China     30     NR        136.6       21.45    30     NR        29.4     10.62    8
  Zhou^*∗∗*^ \[[@B67]\]       2005   China     30     NR        79.63       15.96    30     NR        29.4     10.62    8

DM: diabetes mellitus; SZ: sample size; M/F: man/female; SD: standard deviation; NR: not reported. ^*∗*,*∗∗*^T2DM with different complication; ^a,b,c^T2DM with different duration limited.

###### 

Characteristics of studies about TNF-*α* (pg/mL) included in this meta-analysis.

  Author                    Year   Country   Case   Control   NOS score                                        
  ------------------------- ------ --------- ------ --------- ----------- ------ ----- --------- ------ ------ ---
  Plomgaard^a^ \[[@B34]\]   2007   Denmark   96     72/24     2.72        0.8    103   70/33     2.4    0.54   8
  Yaturu^*∗*^ \[[@B68]\]    2008   USA       50     NR        4           0.36   59    NR        3.4    0.29   7
  Yaturu \[[@B68]\]         2008   USA       26     NR        4.2         0.47   39    NR        3.2    0.32   8
  Lin \[[@B69]\]            2015   China     42     20/22     5.49        1.48   30    14/16     3.46   0.58   8
  Lin^*∗*^ \[[@B69]\]       2015   China     45     25/20     6.82        2.97   30    14/16     3.46   0.58   8
  Volpe \[[@B35]\]          2014   Brazil    29     10/19     78.7        32.7   16    5/11      58.5   29.5   7
  Yeo \[[@B36]\]            2010   Korea     55     27/28     1.5         0.95   488   257/231   1.1    0.31   7
  Lukic \[[@B38]\]          2014   Serbia    30     NR        1.53        0.42   15    NR        0.71   0.3    8
  Lukic^*∗*^ \[[@B38]\]     2014   Serbia    30     NR        1.54        0.41   15    NR        0.71   0.3    8
  Daniele \[[@B45]\]        2014   USA       17     13/4      2.5         0.3    15    7/8       1.5    0.3    7

DM: diabetes mellitus; SZ: sample size; M/F: man/female; SD: standard deviation; NR: not reported. ^*∗*^T2DM with complication and ^a^data (mean ± SD) converted from mean (95% CI).

###### 

Characteristics of studies about the percentage of CD4^+^CD25^+^Foxp3^+^Tregs (%) in the CD4^+^ lymphocyte included in this meta-analysis.

  Author                 Year   Country   Case   Control   NOS score                                           
  ---------------------- ------ --------- ------ --------- ----------- -------- ---- ------- -------- -------- ---
  Haseda \[[@B70]\]      2013   Japan     20     8/12      4.94        1.78     30   10/20   5.36     1.54     8
  Li \[[@B71]\]          2011   China     18     14/4      2.8         8.54     18   12/6    5.01     0.13     7
  Li^*∗*^ \[[@B72]\]     2014   China     15     NR        2.32        0.5      21   13/8    4.07     1.39     8
  Li^*∗∗*^ \[[@B72]\]    2014   China     23     NR        2.91        0.73     21   13/8    4.07     1.39     8
  Jing^*∗*^ \[[@B73]\]   2009   China     60     33/27     3.2733      1.5835   15   8/7     3.6216   0.6938   8
  Zhang \[[@B74]\]       2009   China     17     9/8       5.02        3.59     15   8/7     5.07     3.26     7
  Zhang \[[@B75]\]       2012   China     16     11/5      2.21        0.92     19   7/12    2.32     0.6      6

DM: diabetes mellitus; SZ: sample size; M/F: man/female; SD: standard deviation; NR: not reported. ^*∗*,*∗∗*^T2DM with different complication.

###### 

Characteristics of studies about IL-10 (pg/mL) included in this meta-analysis.

  Author                     Year   Country   Case   Control   NOS score                                         
  -------------------------- ------ --------- ------ --------- ----------- ------ ----- ------- -------- ------- ---
  Acharya^*∗*^ \[[@B76]\]    2015   India     15     NR        11.35       0.97   15    NR      15.83    2.52    8
  Dworacka^*∗*^ \[[@B77]\]   2015   Poland    30     17/13     4.1         1.5    30    12/13   3.8      0.9     7
  You-fei \[[@B78]\]         2009   China     30     14/16     45.859      7.34   30    13/17   18.181   5.145   7
  Ling-Xia \[[@B79]\]        2013   China     20     10/10     8.41        1.22   20    10/10   17.56    1.13    7
  Li \[[@B80]\]              2014   China     63     4/6       15.69       3.22   57    5/5     24.13    2.17    8
  Chen \[[@B81]\]            2014   China     24     NR        5.8         0.9    25    19/11   6.93     0.89    7
  Lu^*∗*^ \[[@B81]\]         2014   China     22     NR        3.12        1.03   25    19/11   6.93     0.89    7
  Hong \[[@B82]\]            2007   China     46     22/24     4.61        1.2    39    19/20   4.36     0.84    7
  Al-Shukaili \[[@B83]\]     2013   Oman      57     28/29     6.95        6      30    20/10   2.9      5.15    8
  Xiaojing \[[@B84]\]        2008   China     42     27/15     4.36        2.64   40    25/15   3.64     3.15    7
  Yue-Ying \[[@B85]\]        2010   China     34     19/15     4           1.4    50    22/28   4.5      1.6     8
  Yue-Ying^*∗*^ \[[@B85]\]   2010   China     50     24/26     2.7         0.9    50    22/28   4.5      1.6     8
  Wei \[[@B86]\]             2013   China     39     NR        5.11        1.33   40    NR      4.56     1.27    7
  Wei^*∗*^ \[[@B86]\]        2013   China     39     NR        10.52       2.43   40    NR      4.56     1.27    7
  Jing \[[@B87]\]            2013   China     20     11/9      5           2.16   30    NR      5.07     1.32    7
  Jing^*∗*^ \[[@B87]\]       2013   China     30     19/11     7.58        2.67   30    NR      5.07     1.32    7
  Yaghini \[[@B88]\]         2011   Iran      131    NR        9.53        2.27   120   NR      16.11    2.27    7
  Hua \[[@B89]\]             2015   China     61     NR        6.98        2.84   40    NR      5.83     1.37    8
  Hua^*∗*^ \[[@B89]\]        2015   China     52     NR        30.7        9.28   40    NR      5.83     1.37    8
  Zhao-Hui \[[@B90]\]        2014   China     50     26/24     8.39        1.18   50    24/26   17.63    1.22    8
  Zhao-Hui^*∗*^ \[[@B90]\]   2014   China     50     28/22     1.86        0.33   50    24/26   17.63    1.22    8

DM: diabetes mellitus; SZ: sample size: M/F: man/female; SD: standard deviation; NR: not reported. ^*∗*^T2DM with complication.

###### 

Characteristics of studies about the percentage of CD4^+^CD25^+^Tregs (%) in the CD4^+^ lymphocyte included in this meta-analysis.

  Author                   Year   Country    Case   Control   NOS score                                      
  ------------------------ ------ ---------- ------ --------- ----------- ------ ---- ------- ------- ------ ---
  Afzal \[[@B91]\]         2014   Pakistan   30     5/25      14.68       6.21   30   21/9    14.53   4.84   8
  Afzal^*∗*^ \[[@B91]\]    2014   Pakistan   152    51/101    16.47       6.56   30   21/9    14.53   4.84   8
  Chi \[[@B92]\]           2011   China      52     30/22     9.39        2.12   40   20/20   10.43   2.07   7
  Chi^*∗*^ \[[@B92]\]      2011   China      68     39/29     8.99        2.03   40   20/20   10.43   2.07   7
  Haseda \[[@B70]\]        2013   Japan      20     8/12      27.7        11.1   30   10/20   24.9    6.5    7
  Ling \[[@B93]\]          2006   China      25     12/13     1.3         0.6    27   13/14   1.3     0.4    8
  Ling \[[@B93]\]          2006   China      20     13/7      13.76       3.27   21   10/11   12.98   3.14   8
  Kukreja \[[@B94]\]       2002   USA        15     2/13      6.3         0.48   26   12/14   6.9     0.4    8
  Hong \[[@B95]\]          2011   China      20     10/10     5.35        2.12   25   15/10   4.06    1.39   7
  Hong^*∗*^ \[[@B95]\]     2011   China      18     10/8      9.8         7.27   25   15/10   4.06    1.39   7
  Li^*∗*^ \[[@B96]\]       2012   China      20     10/10     6.24        1.96   30   18/12   4.24    1.5    7
  Ye-Hai^*∗*^ \[[@B97]\]   2011   China      81     NR        6.05        1.2    38   NR      2.01    0.73   7
  Li^*∗*^ \[[@B72]\]       2014   China      15     NR        9.14        2.21   21   13/8    15.18   3.6    7
  Li^*∗∗*^ \[[@B72]\]      2014   China      13     NR        10.69       2.75   21   13/8    15.18   3.6    7
  Wu^*∗*^ \[[@B98]\]       2015   China      10     NR        2.1         1.5    20   12/8    2.3     2.2    8
  Yang \[[@B99]\]          2007   China      30     18/12     9.84        4.78   30   18/12   8.16    3.65   8
  Yang \[[@B100]\]         2014   China      43     19/24     2.02        0.43   52   28/24   2.89    0.39   6
  Xue-he \[[@B101]\]       2009   China      22     9/13      6.79        1.75   17   8/9     7.84    1.45   7
  Zhang \[[@B74]\]         2009   China      17     9/8       8.5         4.16   15   8/7     8.83    3.87   8
  Zhang \[[@B102]\]        2010   China      37     24/13     0.5         0.8    38   21/17   0.7     1      7
  Zhang^*∗*^ \[[@B102]\]   2010   China      40     26/14     4.7         2.3    38   21/17   0.7     1      7
  Tao \[[@B103]\]          2011   China      20     NR        3.74        0.89   20   NR      3.78    0.95   8
  Zhang \[[@B75]\]         2012   China      16     11/5      5.29        2.6    19   7/12    9.75    2.13   7
  Zhang \[[@B104]\]        2013   China      36     19/17     8.8         3.6    20   11/9    12.4    1.5    7
  Zhang^*∗*^ \[[@B104]\]   2013   China      30     16/14     6.05        1.06   20   11/9    12.4    1.5    7

DM: diabetes mellitus; SZ: sample size; M/F: man/female; SD: standard deviation; NR: not reported. ^*∗*,*∗∗*^T2DM with different complication.

###### 

Characteristics of studies about IL-17 (pg/mL) included in this meta-analysis.

  Author                            Year   Country    Case   Control   NOS score                                             
  --------------------------------- ------ ---------- ------ --------- ----------- --------- ----- ------- -------- -------- ---
  Pernet Hara \[[@B105]\]           2016   Brazil     15     0/15      6.98        1.11      10    0/10    16.2     4.39     8
  Suzuki^*∗*^ \[[@B106]\]           2011   Japan      56     25/31     147.39      113.83    30    2/28    154.52   117.99   7
  Afzal \[[@B107]\]                 2014   Pakistan   30     5/25      415.01      483.4     30    21/9    718.05   756.55   7
  Afzal^*∗*^ \[[@B107]\]            2014   Pakistan   152    51/101    375.95      468.19    30    21/9    718.05   756.55   7
  Arababadi \[[@B108]\]             2010   Iran       100    41/59     13.7        2.34      100   40/60   4.43     0.54     8
  Arababadi^*∗*^ \[[@B108]\]        2010   Iran       100    38/62     0.94        0.29      100   40/60   4.43     0.54     8
  Liu^*∗*^ \[[@B109]\]              2016   China      19     10/9      21.4        5.9       20    8/12    17.3     6.2      7
  Roohi \[[@B110]\]                 2014   India      38     19/19     6.61        4.97      40    22/18   6.22     4.64     8
  Zhan^*∗*^ \[[@B111]\]             2015   China      30     14/16     42.24       67.7      30    14/16   9.33     8.15     8
  Kologrivova^*∗*a^ \[[@B112]\]     2014   Russia     35     17/18     100.83      42.7      24    NR      45.29    54.85    7
  Bilir^b^ \[[@B113]\]              2016   Turkey     33     15/18     466.1       183.075   33    15/18   205.2    67.725   6
  Bilir^*∗*b^ \[[@B113]\]           2016   Turkey     37     17/20     454.9       189.825   33    15/18   205.2    67.725   6
  Vasanthakumar^c^ \[[@B114]\]      2015   India      65     38/27     59.8        2.8       88    35/53   94.7     12.75    6
  Vasanthakumar^*∗*c^ \[[@B114]\]   2015   India      97     57/40     67.4        2.275     88    35/53   94.7     12.75    6

DM: diabetes mellitus; SZ: sample size; M/F: man/female; SD: standard deviation; NR: not reported. ^*∗*^T2DM with complication; ^a^data converted from median (interquartile); ^b^data converted from median (range); ^c^data converted from geometrical mean (range).

[^1]: Academic Editor: Bernard Portha
